MARTINSRIED, GERMANY and MUNCHEN, GERMANY--(Marketwire - May 17, 2012) -
MorphoSys AG /
MorphoSys to Present MOR208 Preclinical Combination Therapy Data at ASCO
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Synergistic Effects Seen with Four Approved Treatment Options Including
Rituximab and Ofatumumab
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) today
promising pre-clinical data on its proprietary drug candidate MOR208.
(formerly XmAb(®)5574) is a potent anti-CD19 antibody with a
modification to the Fc portion that is being developed to treat
malignancies. The pre-clinical data, which will be presented at the
Meeting of the American Society of Clinical Oncology (ASCO) on June 4,
demonstrate the potential for four different combination therapies with
in models of lymphoma.
"Combination therapies including antibodies represent a promising
more efficacious anti-tumor therapy," commented Dr. Arndt Schottelius,
Development Officer of MorphoSys AG. "These intriguing results provide a
rationale for MOR208 drug combinations which warrant further
MOR208 is an Fc-engineered, humanized, anti-CD19 antibody with
cytotoxicity in a number of in vitro and in vivo models of
leukemia. The antibody is currently being evaluated in patients
relapsed/refractory chronic lymphocytic leukemia. In the preclinical
which will be presented in full at the ASCO meeting, approved therapeutic
including the small-molecule drugs bendamustine (Ribomustin(®)) and
(Fludara(®)) as well as the anti-CD20 antibodies rituximab
ofatumumab (Arzerra(®)) were evaluated for their ability to
cytotoxicity of MOR208. The in vitro and in vivo activities of MOR208
aggressive lymphoma model were synergistically enhanced by all applied
independent of their different modes of action.
In June 2010, MorphoSys AG and Xencor signed a collaboration agreement,
provided MorphoSys with an exclusive worldwide license to MOR208. The
has been engineered to possess significantly enhanced antibody-dependent
cell-mediated cytotoxicity (ADCC), thus improving a key mechanism for
killing and offering potential for enhanced efficacy compared to
antibodies for the treatment of cancer. MorphoSys will be solely
further clinical development after successful completion of the currently
phase 1 clinical trial. The Company plans to initiate additional clinical
for MOR208 in non-Hodgkin's lymphoma (NHL) and acute lymphoblastic
(ALL) by the end of 2012.
MO208 represents one of four proprietary clinical programs
currently pursuing. The Company's proprietary portfolio also comprises
fully human HuCAL antibody directed against GM-CSF (granulocyte
macrophage-colony stimulating factor), currently in development in RA and
MS, as well as
MOR202, a HuCAL antibody targeting CD38, which is being evaluated in
MorphoSys developed HuCAL, the most successful antibody library
the pharmaceutical industry. By successfully applying this and other
technologies, MorphoSys has become a leader in the field of
antibodies, one of the fastest-growing drug classes in human
company's AbD Serotec unit uses HuCAL and other antibody
generate superior monoclonal antibodies for research and
Together with its pharmaceutical partners, MorphoSys has built a
pipeline of more than 70 human antibody drug candidates for the
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few.
its ongoing commitment to new antibody technology and drug
MorphoSys is focused on making the healthcare products of tomorrow.
listed on the Frankfurt Stock Exchange under the symbol MOR. For regular
about MorphoSys, visit http://www.morphosys.com
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®,
RapMAT® and arYla® are registered trademarks of MorphoSys AG.
XmAb® is a registered trademark of Xencor, Inc.
Ribomustin® is a registered trademark of Astellas.
Fludara® is a registered trademark of Genzyme/Sanofi Aventis.
Rituxan® is a registered trademark of Genentech/Roche.
Arzerra® is a registered trademark of GlaxoSmithKline.
This communication contains certain forward-looking statements
MorphoSys group of companies. The forward-looking statements contained
represent the judgment of MorphoSys as of the date of this release and
risks and uncertainties. Should actual conditions differ from the
assumptions, actual results and actions may differ from those
MorphoSys does not intend to update any of these forward-looking
far as the wording of the relevant press release is concerned.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE